Xarelto Update: First Federal MDL Trial Verdict

May 11th, 2017

The first multi-district litigation (MDL) trial for the blood thinner medication Xarelto began just a few weeks ago. This drug is used to prevent blood clots in patients suffering from arrhythmic heart disorder. If not properly monitored, Xarelto increases the risk of severe internal bleeding. The legal team representing Xarelto victims argues that the manufacturer of the drug failed to properly warn the medical community of the danger of uncontrollable bleeding presented by Xarelto. Sadly, there is no known antidote or treatment to stop the bleeding resulting from Xarelto use. This defective drug has shattered the lives of thousands of innocent persons who took Xarelto and suffered serious injuries and death from excessive gastrointestinal and cranial bleeding.

On May 3, 2017, a Louisiana federal court jury ruled in favor of the manufacturer of Xarelto, Bayer Pharmaceuticals, a subsidiary of Johnson & Johnson. This is the first of four MDL cases to be tried over the next several months. The case was decided by the jury based on the learned intermediary doctrine, a legal principle which limits the responsibility of drug manufacturers to warn individual patients. Under this doctrine, the manufacturer is only obligated to appropriately advise medical professionals about the drug’s dangerous side effects. Although the jury’s recent verdict is disappointing, their decision has absolutely no bearing on future cases. Lawyers will continue to press forward in the fight to obtain justice for Xarelto victims.

There are over 18,000 other Xarelto lawsuits currently pending in the United States. Attorneys for Xarelto victims continue to maintain that the manufacturer of this defective drug breached its legal duty to fully warn users of the dangerous risks of Xarelto. With the large number of lawsuits filed by victims suffering from the serious complications of taking Xarelto, Bayer and Johnson & Johnson will face considerable pressure to be held responsible for their defective drug in the upcoming MDL trials.

Our experienced lawyers fight for individuals who have been harmed by defective drugs. If you or a loved one has suffered from serious internal bleeding after using the blood thinner Xarelto, the attorneys at the Yost Legal Group will investigate the claim. For a free consultation, please call us at 1-800-YOSTLAW. At The Yost Legal Group, there is no fee or expense unless you recover.

Manufacturers of Xarelto are Being Investigated for their Marketing Strategies

Drug companies Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, and Bayer Healthcare are being investigated by attorneys for their marketing strategies. For the blood-thinning drug Xarelto (rivaroxaban), these strategies were aimed at putting profits over safety. Even though Xarelto was said to surpass all other drugs of its kind in effectiveness, safety and ease of use, it turned out to be life-threatening for many users. Xarelto, approved by the FDA in 2011, was prescribed…

Read More »

Blood Thinner Medication Xarelto is Causing Severe Adverse Reactions baltimore defective drug lawyers, product liability attorneys in maryland, defective product law firm, medication error, side effects, Xarelto lawsuit

Earlier this year, The Yost Legal Group outlined the underlying factors of a Multidistrict Litigation (MDL) against the blood-thinner medication Xarelto. Since the announcement of this litigation at the end of 2014, a case that already appeared primed to become one of 2015’s largest mass tort drug cases has continued to grow as new patients harmed by this medication continue to come forward. The case against Xarelto and manufacturer Janssen Pharmaceuticals, a subsidiary of Johnson…

Read More »

Blood-Thinner Drug Xarelto Markets Convenience, But Puts Patients In Grave Danger defective drug lawyers baltimore, xarelto lawsuit, maryland product liability law firm, consumer safety

One of the first major drug torts of 2015 will center on the controversial anticoagulant medication known as Xarelto. Manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals as well as Bayer Corporation, Xarelto is part of a new breed of blood thinning drugs known as New Oral Anti-Coagulants (NOACs).   What’s new is that unlike the longstanding go-to drug Coumadin (Warfarin), this new generation of drugs promises the convenience of freedom from dietary restrictions and the…

Read More »